MCID: ADL027
MIFTS: 38

Adult Dermatomyositis

Categories: Bone diseases, Eye diseases, Muscle diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Adult Dermatomyositis

MalaCards integrated aliases for Adult Dermatomyositis:

Name: Adult Dermatomyositis 12 15
Adult Onset Dermatomyositis 12
Adult Type Dermatomyositis 74

Classifications:



External Ids:

Disease Ontology 12 DOID:14202
UMLS 74 C0221056

Summaries for Adult Dermatomyositis

MalaCards based summary : Adult Dermatomyositis, also known as adult onset dermatomyositis, is related to childhood type dermatomyositis and dermatomyositis. An important gene associated with Adult Dermatomyositis is MBL2 (Mannose Binding Lectin 2), and among its related pathways/superpathways are Transcription_Role of VDR in regulation of genes involved in osteoporosis and RXR and RAR heterodimerization with other nuclear receptor. The drugs Pirfenidone and Abatacept have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and bone.

Related Diseases for Adult Dermatomyositis

Diseases in the Dermatomyositis family:

Adult Dermatomyositis

Diseases related to Adult Dermatomyositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Related Disease Score Top Affiliating Genes
1 childhood type dermatomyositis 32.1 DMBX1 SAE1
2 dermatomyositis 11.8
3 vulvar vestibulitis syndrome 10.2 MBL2 TNF
4 streptococcal meningitis 10.2 MBL2 TNF
5 meningitis 10.2 MBL2 TNF
6 listeriosis 10.2 MBL2 TNF
7 opisthorchiasis 10.2 GPT TNF
8 nonalcoholic steatohepatitis 10.2 GPT TNF
9 rheumatic fever 10.2 MBL2 TNF
10 calcinosis 10.2
11 hemorrhagic fever 10.2 GPT TNF
12 scrub typhus 10.2 GPT TNF
13 bacterial vaginosis 10.2 MBL2 TNF
14 rheumatic heart disease 10.2 MBL2 TNF
15 protein-energy malnutrition 10.2 GPT TNF
16 hepatitis e 10.2 GPT TNF
17 compartment syndrome 10.2 CHKB TNF
18 endometritis 10.1 CHKB TNF
19 hepatitis a 10.1 GPT TNF
20 aspergillosis 10.1 MBL2 TNF
21 obstructive jaundice 10.1 GPT TNF
22 hepatic encephalopathy 10.1 GPT TNF
23 alcoholic hepatitis 10.1 GPT TNF
24 polymyositis 10.1
25 cerebral palsy 10.1 MBL2 TNF
26 portal hypertension 10.1 GPT TNF
27 otitis media 10.1 MBL2 TNF
28 cholangitis 10.1 GPT TNF
29 multidrug-resistant tuberculosis 10.1 TNF VDR
30 rosacea 10.1 TNF VDR
31 lepromatous leprosy 10.1 TNF VDR
32 prostatitis 10.1 TNF VDR
33 kawasaki disease 10.1 MBL2 TNF
34 viral hepatitis 10.1 GPT TNF
35 bacterial infectious disease 10.0 MBL2 TNF
36 hepatitis b 10.0 GPT MBL2 TNF
37 systemic lupus erythematosus 10.0
38 lupus erythematosus 10.0
39 panniculitis 9.9
40 pneumonia 9.9 MBL2 TNF
41 mouth disease 9.9 TNF VDR
42 myositis 9.9
43 pneumatosis cystoides intestinalis 9.9
44 pulmonary tuberculosis 9.9 MBL2 TNF VDR
45 mycobacterium tuberculosis 1 9.9 MBL2 TNF VDR
46 nasopharyngeal carcinoma 9.8
47 lipodystrophy, partial, acquired 9.8
48 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 9.8
49 viral infectious disease 9.8 GPT TNF
50 renal cell carcinoma, nonpapillary 9.7

Graphical network of the top 20 diseases related to Adult Dermatomyositis:



Diseases related to Adult Dermatomyositis

Symptoms & Phenotypes for Adult Dermatomyositis

Drugs & Therapeutics for Adult Dermatomyositis

Drugs for Adult Dermatomyositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 142)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pirfenidone Approved, Investigational Phase 4,Phase 3 53179-13-8 40632
2
Abatacept Approved Phase 4,Phase 3,Phase 2 332348-12-6 10237
3 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Vaccines Phase 4,Not Applicable
11 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Melanocyte-Stimulating Hormones Phase 4,Phase 2
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Adrenocorticotropic Hormone Phase 4,Phase 2
15 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
16 beta-endorphin Phase 4,Phase 2
17 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18
leucovorin Approved Phase 3,Phase 2 58-05-9 6006 143
19
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
20
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
21
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2 2921-57-5
22
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2 22916-47-8 4189
23
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
24
Prednisone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 53-03-2 5865
25
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2 302-25-0
26
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
27
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 445643 439492 6473866
28
tannic acid Approved Phase 2, Phase 3 1401-55-4
29
Benzocaine Approved, Investigational Phase 2, Phase 3 94-09-7, 1994-09-7 2337
30
Alendronate Approved Phase 2, Phase 3 66376-36-1, 121268-17-5 2088
31
Infliximab Approved Phase 2, Phase 3 170277-31-3
32
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 6055-19-2, 50-18-0 2907
33
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
34
Etanercept Approved, Investigational Phase 2, Phase 3,Phase 1 185243-69-0
35
belimumab Approved Phase 2, Phase 3 356547-88-1 5957 10451420
36
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
38
Prednisolone hemisuccinate Experimental Phase 3,Phase 2 2920-86-7
39 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
40 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Not Applicable
41 Antimetabolites, Antineoplastic Phase 3,Phase 2
42 Folate Phase 3,Phase 2
43 Antiemetics Phase 3,Phase 2
44 Methylprednisolone Acetate Phase 3,Phase 2
45 Vitamin B9 Phase 3,Phase 2
46 Folic Acid Antagonists Phase 3,Phase 2
47 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
48 Calcineurin Inhibitors Phase 3,Phase 2
49 glucocorticoids Phase 3,Phase 2,Phase 1,Not Applicable
50 Protective Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 101)
# Name Status NCT ID Phase Drugs
1 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
2 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
3 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
4 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Completed NCT03226119 Phase 4
5 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4 H.P. Acthar Gel
6 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
7 Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
8 Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM) Completed NCT00335985 Phase 3 GB-0998;Placebo of GB-0998
9 Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM Completed NCT00651040 Phase 3 Prednisone;Methotrexate
10 Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus Completed NCT00504348 Phase 2, Phase 3 Tacrolimus
11 Alendronate Osteoporosis Study Completed NCT00277251 Phase 2, Phase 3 Alendronate
12 Anakinra in Myositis Completed NCT01165008 Phase 2, Phase 3 Anakinra
13 Treatment With TNF Blockade, Infliximab, in Patients With Myositis Completed NCT00443222 Phase 2, Phase 3 Infliximab
14 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis Recruiting NCT03813160 Phase 3 Lenabasum 20 mg;Lenabasum 5 mg;Placebo
15 Efficacy and Safety of Pirfenidone in Patient With Dermatomyositis Interstitial Lung Disease (Dm-ILD) Recruiting NCT03857854 Phase 3 Pirfenidone;Placebos
16 Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD Recruiting NCT01862926 Phase 2, Phase 3 Rituximab;Cyclophosphamide
17 Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy Recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
18 Belimumab in Idiopathic Inflammatory Myositis Recruiting NCT02347891 Phase 2, Phase 3 Belimumab;Placebo
19 Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) Active, not recruiting NCT02728752 Phase 3 Octagam 10%
20 Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis Terminated NCT03686969 Phase 3 Octanorm
21 Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3 Prednisone;Methotrexate;Etanercept
22 A Clinical Trial for CTD-ILD Treatment Terminated NCT01424033 Phase 2, Phase 3 N-Acetylcysteine
23 Abatacept Treatment in Polymyositis and Dermatomyositis Unknown status NCT01315938 Phase 2 Abatacept;Abatacept
24 Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis Completed NCT01572844 Phase 2 Sodium thiosulfate
25 Trial of IMO-8400 in Adult Patients With Dermatomyositis Completed NCT02612857 Phase 2 IMO-8400 Dose Group 1;IMO-8400 Dose Group 2;Placebo
26 Acthar in Treatment of Refractory Dermatomyositis and Polymyositis Completed NCT01906372 Phase 2 Adrenocorticotropic Hormone Gel
27 Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis Completed NCT00005571 Phase 2 h5G1.1-mAb
28 Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis Completed NCT01415219 Phase 2
29 Methimazole to Treat Polymyositis and Dermatomyositis Completed NCT00001421 Phase 2 methimazole
30 Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis Completed NCT00033891 Phase 2 Infliximab
31 Absorption of Corticosteroids in Children With Juvenile Dermatomyositis Completed NCT00004357 Phase 2 Methylprednisolone;Prednisolone
32 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) Completed NCT00106184 Phase 2 Rituximab;Placebo
33 Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies Completed NCT00001261 Phase 2 Gamma Globulin
34 A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis Completed NCT00979654 Phase 2 Sifalimumab
35 Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis Recruiting NCT03529955 Phase 2 Apremilast 30mg
36 Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Recruiting NCT03267277 Phase 2 Sodium Thiosulfate
37 A Study In Adults With Moderate To Severe Dermatomyositis Recruiting NCT03181893 Phase 2 PF-06823859;Placebo Arm
38 Study of IFN-K in Dermatomyositis Recruiting NCT02980198 Phase 2
39 Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Recruiting NCT02043548 Phase 2 tocilizumab;placebo
40 Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis Active, not recruiting NCT02466243 Phase 2 JBT-101;Placebo
41 Basiliximab Treating Interstitial Pneumonia of CADM Not yet recruiting NCT03192657 Phase 2 Basiliximab;Calcineurin Inhibitors;Steroids
42 Intralesional Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study Not yet recruiting NCT03582800 Phase 2 STS
43 Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders Not yet recruiting NCT02418273 Phase 1, Phase 2 denosumab
44 Safety and Efficacy of BAF312 in Dermatomyositis Terminated NCT02029274 Phase 2 BAF312;Placebo
45 Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis Terminated NCT01148810 Phase 2 BAF312;Placebo
46 A Pilot Study to Evaluate Topical Sodium Thiosulfate Therapy for Calcinosis Cutis Withdrawn NCT01918904 Phase 2 Sodium thiosulfate;Placebo
47 Evaluation of the Safety and Effectiveness of Tailored Transoral Incisionless Fundoplication (TIF) Using EsophyX for the Treatment of GERD Withdrawn NCT01025739 Phase 2
48 A Pilot Study of Etanercept in Dermatomyositis Completed NCT00112385 Phase 1 Etanercept;Placebo
49 A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis Completed NCT00533091 Phase 1
50 A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases Completed NCT02780674 Phase 1

Search NIH Clinical Center for Adult Dermatomyositis

Genetic Tests for Adult Dermatomyositis

Anatomical Context for Adult Dermatomyositis

MalaCards organs/tissues related to Adult Dermatomyositis:

42
Skin, Lung, Bone, Heart, Eye, Colon

Publications for Adult Dermatomyositis

Articles related to Adult Dermatomyositis:

(show top 50) (show all 93)
# Title Authors Year
1
Biomarkers in Adult Dermatomyositis: Tools to Help the Diagnosis and Predict the Clinical Outcome. ( 30766892 )
2019
2
The IgG2 isotype of anti-transcription intermediary factor 1-gamma autoantibodies is a biomarker of mortality in adult dermatomyositis. ( 30896088 )
2019
3
Acquired Partial Lipodystrophy Associated with Anti-Mi-2 Antibody-positive Adult-onset Dermatomyositis. ( 30182133 )
2019
4
Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. ( 28993346 )
2018
5
Use of Anti-transcriptional Intermediary Factor-1 Gamma Autoantibody in Identifying Adult Dermatomyositis Patients with Cancer: A Systematic Review and Meta-analysis. ( 30460368 )
2018
6
Comparison between treatment naive juvenile and adult dermatomyositis muscle biopsies: difference of inflammatory cells phenotyping. ( 30657098 )
2018
7
Association of antinuclear antibody status with clinical features and malignancy risk in adult-onset dermatomyositis. ( 30458207 )
2018
8
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. ( 28385805 )
2017
9
Environmental factors associated with disease flare in juvenile and adult dermatomyositis. ( 28444299 )
2017
10
The cutaneous and systemic findings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. ( 28129490 )
2017
11
Gene Expression Profiling in Blood and Affected Muscle Tissues Reveals Differential Activation Pathways in Patients with New-onset Juvenile and Adult Dermatomyositis. ( 27803134 )
2017
12
Liposteroid therapy for juvenile and adult dermatomyositis: efficacy and side effects. ( 28361075 )
2017
13
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects. ( 28977549 )
2017
14
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. ( 28382787 )
2017
15
Extensive calcinosis in adult dermatomyositis. ( 28396153 )
2017
16
Calcinosis universalis in adult-onset dermatomyositis. ( 27377452 )
2017
17
Association of vitamin D receptor gene BsmI B/b and FokI F/f polymorphisms with adult dermatomyositis and systemic lupus erythematosus. ( 26972080 )
2016
18
Colonic vasculopathy and perforation in the initial presentation of adult dermatomyositis in a patient with improving muscle weakness. ( 26759443 )
2016
19
Universalis Calcinosis in Adult Dermatomyositis: An "Anti-NXP2 Syndrome". ( 27660942 )
2016
20
Differential roles of hypoxia and innate immunity in juvenile and adult dermatomyositis. ( 27121733 )
2016
21
Adult dermatomyositis associated with benign ovarian teratoma: A case report. ( 27073526 )
2016
22
Anti-TIF1-I^-positive young adult dermatomyositis with germ cell tumour. ( 27457276 )
2016
23
Clinico pathological study of adult dermatomyositis: Importance of muscle histology in the diagnosis. ( 26019418 )
2015
24
Severe adult dermatomyositis with unusual calcinosis. ( 26286744 )
2015
25
Gastrointestinal endarteropathy in adult dermatomyositis. ( 26184526 )
2015
26
Calcific panniculitis and nasopharyngeal cancer-associated adult-onset dermatomyositis: a case report and literature review. ( 25977892 )
2015
27
Adult dermatomyositis with bleeding ulcer in the pharynx. ( 25328739 )
2014
28
A case of adult dermatomyositis with calcinosis universalis. ( 25400376 )
2014
29
IL-1RN VNTR Polymorphism in Adult Dermatomyositis and Systemic Lupus Erythematosus. ( 25328514 )
2014
30
HLA class II alleles may influence susceptibility to adult dermatomyositis and polymyositis in a Han Chinese population. ( 24894810 )
2014
31
Unusual sequelae of adult-onset dermatomyositis. ( 25085949 )
2014
32
Analysis of metabolic syndrome in adult dermatomyositis with a focus on cardiovascular disease. ( 23139205 )
2013
33
Adult dermatomyositis associated with lipodystrophy. ( 23962582 )
2013
34
Focal lipodystrophy without metabolic disorders in adult dermatomyositis. ( 22804743 )
2013
35
Lacy reticular-pattern calcinosis in adult dermatomyositis. ( 23908532 )
2013
36
Therapy of calcinosis universalis complicating adult dermatomyositis. ( 24131911 )
2013
37
A case of adult dermatomyositis associated with parainfluenza virus infection and Jo-1 antibody. ( 24341326 )
2013
38
Renal cell carcinoma-associated adult dermatomyositis treated laparoscopic nephrectomy. ( 24311917 )
2013
39
MBL2 polymorphisms - manifestations in bulgarian patients with adult dermatomyositis and systemic lupus erythematosus. ( 24103065 )
2013
40
Association of TNF-I+ polymorphisms with adult dermatomyositis and systemic lupus erythematosus in Bulgarian patients. ( 22913362 )
2012
41
Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. ( 22886447 )
2012
42
Marked improvement of calcinosis in adult dermatomyositis with etidronate therapy. ( 21710176 )
2012
43
Adult dermatomyositis: experience of a Brazilian tertiary care center. ( 23223700 )
2012
44
Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. ( 21947177 )
2011
45
Adult dermatomyositis with severe polyneuropathy: does neuromyositis exist? ( 20229079 )
2010
46
An extremely severe case of cutaneous calcinosis complicating adult dermatomyositis. ( 19076816 )
2009
47
Clinical characteristics and outcomes of juvenile and adult dermatomyositis. ( 19654958 )
2009
48
Case of pneumatosis cystoides intestinalis in adult dermatomyositis. ( 18181780 )
2008
49
Tracheoesophageal fistula: a rare complication of adult dermatomyositis. ( 18474474 )
2008
50
Calcinosis cutis: a rare feature of adult dermatomyositis. ( 18319027 )
2008

Variations for Adult Dermatomyositis

Expression for Adult Dermatomyositis

Search GEO for disease gene expression data for Adult Dermatomyositis.

Pathways for Adult Dermatomyositis

Pathways related to Adult Dermatomyositis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.61 TNF VDR
2 9.77 TNF VDR

GO Terms for Adult Dermatomyositis

Biological processes related to Adult Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription, DNA-templated GO:0045892 9.43 VDR TNF DMBX1
2 defense response to Gram-positive bacterium GO:0050830 9.16 TNF MBL2
3 positive regulation of phagocytosis GO:0050766 8.96 TNF MBL2
4 negative regulation of growth of symbiont in host GO:0044130 8.62 TNF MBL2

Molecular functions related to Adult Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 8.8 DMBX1 TNF VDR

Sources for Adult Dermatomyositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....